Global Analgesics Industry

  • October 2010
  • -
  • Global Industry Analysts

This report analyzes the worldwide markets for Analgesics in US$ Million by the following segments: Internal Analgesics, (Aspirin, Acetaminophen, Ibuprofen, and Others (includes combination drugs)), and External Analgesics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A six-year historic analysis is also provided for these markets. The report profiles 137 companies including many key and niche players such as Bayer Consumer Care, Johnson & Johnson, McNeil Consumer Healthcare, Novartis International AG, Pfizer, Inc., Reckitt Benckiser Group Plc, and Sanofi Aventis S.A. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table Of Contents


ANALGESICS MCP-5064
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


1. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation and Reporting Level 2
Quantitative Techniques and Analytics 3
Product Definitions and Scope of Study 3
1. Internal Analgesics 3
Aspirin 3
Acetaminophen 3
Ibuprofen 4
Others 4
2. External Analgesics 4

2. GLOBAL ANALGESICS MARKET OVERVIEW 5
Pain Therapeutic Market 5
Analgesics Market - Offering Immense Potential 5
Internal Analgesics - The Largest and Fastest Growing Market 5
Liquid Analgesics Register Rapid Growth 6
Neuropathic Pain - Unexplored 6
Ibuprofen Scoring High 6
External Analgesics - Loosing Sheen 6
Topical Analgesics Market: Current Picture 7
Competitive Scenario 7
Global Analgesics Market (2007): Leading Analgesics Brands by
Manufacturer 7

3. PRODUCT OVERVIEW 8
A Brief History 8
Analgesics 8
Definition 8
Types of Pain 8
Acute Pain 8
Chronic Pain 9
Drugs Combating Pain 9
Local Anesthetics 9
Narcotic Opioids 10
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 10
Types of NSAIDS 10
Common NSAIDs 11
Clinical Use... 12
Side Effects... 12
Aspirin 13
The Wonder Drug... 13
PolyAspirin: The Safer and More Potent Polymer Variant of
Aspirin 13
Mode of Action 13
Contraindications 14
Acetaminophen 14
Acetaminophen Protects Heart Muscle 14
Acetaminophen Reduces Incidence of Ovarian Cancer 15
Ibuprofen, Ketoprofen and Naproxen 15
Combination Analgesics 15
Table 1: Opioid Analgesics Market: Percentage Share of Opioid
/ Acetaminophen Combination Products in the Opioid Script
Volume (includes corresponding Graph/Chart) 16
OTC Analgesics: An Overview 16

4. INDUSTRY DYNAMICS 17
Escalating RandD Costs: A Boon or Bane? 17
Timeline of the Drug Approval Process 17
Cox II Crisis Tarnishes Industry Growth 17
Novel Therapies to Propel Opioid and Non-Opioid Therapies 18
Rx-to-OTC Switch 18
Why Consumers Prefer OTC Drugs? 18
Development of Analgesic Tripeptides 18

5. RECENT CLINICAL TRIALS 19
PLx Initiates Clinical Trial For Aspirin-PC 19
Neurodiscovery Receives Approval for NSL-101 Phase II Clinical
Trials 19

6. PRODUCT INTRODUCTIONS/INNOVATIONS 20
Victory Pharma Unveils Naprelan Dose Card 20
Nutra Pharma Commences Online Sales of Cobroxin 20
Nutra Pharma to Introduce Nyloxin Rx 20
Dr Reddy’s Rolls Out Finrid 20
MIP Technologies and Supelco Introduce Unique SPE Product 21
Novartis Introduces Voltaren AC Product Line 21
ProEthic Pharmaceuticals Releases Ibudone for Acute Pain
Management 21
Dr. Reddy’s Laboratories Introduces Supanac for Acute Pain
Management 21
Teva Pharmaceutical Announces the Launch of Fentanyl
Transdermal System 22
Dr. Reddy's Laboratories Introduces Supanac NSAID Drug 22

7. PRODUCT INNOVATIONS/LAUNCHES IN RECENT PAST - A PERSPECTIVE
BUILDER 23
Mallinckrodt Introduces Magnacetâ„¢ Tablets for Pain Management 23
Wockhardt to Launch New Painkiller 23
Paladin Labs and Labopharm Introduce Triduralâ„¢ 23
Shionogi and Co Introduces OxiNorm Powder 0.5% 23
McNeil Brings Chewable TYLENOL® GoTabs Tablets 23
Barr Unveils Generic Version of ACTIQ® 24
Novartis Launches Voltarol Pain-Eze Emulgel. 24
TheraQuest Launches TQ-1017 24
Mentholatum Company Introduces WellPatch Deep Heat Patch 24

8. PRODUCT APPROVALS 25
Par Pharmaceutical Secures Approval for Marketing Tramadol ER 25
Cipher Acquires Tentative Approval for Tramadol ER Capsules 25
Lannett Receives Approval for Developing Hydromorphone
Hydrochloride Tablets 25
King Pharmaceuticals Receives Approval for Embeda Pain-Relief
Capsules 25
Sangart Secures EC’s Orphan Drug Designation for MP4CO 26
Biovail Secures Canadian Approval for Ralivia 26
Elite Pharmaceuticals and PharmaNetwrok Receive FDA Approval 26

9. RECENT INDUSTRY ACTIVITY 27
China Life Insurance Inks Agreement with Sino Biopharmaceutical 27
Azur Pharma Inks Agreement with Elan Pharmaceuticals 27
Pfizer Acquires Wyeth 27
Taisho Pharmaceutical Takes Over OTC Drugs Business of
Bristol-Myers Squibb 27
Piramal Healthcare Acquires Minrad International 28
Biocon Acquires Bulk Pharmaceuticals Unit of Hindujas 28
Abbott Acquires PG110 from PanGenetics 28
Sanofi-aventis Mexico Takes Over Laboratorios Kendrick 28
WraSer Acquires e5 Pharma’s Trezix 28
Astellas Acquires Exclusive rights to Pain-Relief Drug from
Neuroges 29
Henan Lingrui Pharma Commences Construction of New Analgesic
Factory 29
Labopharm Europe Enters into Agreement with Merck Sharp and Dohme 29
Cumberland Pharmaceuticals Enters into a Commercialization
Agreement with DB Pharm Korea 29
Cumberland Pharmaceuticals Inks an Exclusive Agreement with
Phebra 30
Mallinckrodt Acquires Rights of Exalgo Extended-Release
Tablets from Neuromed 30
Labopharm Europe and Grunenthal Sign Distribution and Supply
Agreement 30
Timm Medical and Ferring Co-promote Prosed DS in the US 30
Competitive Technologies and Fintrade Medical Ink Sales and
Distribution Agreement 31
Accumetrics and Endotech Ink Exclusive Distribution Agreement 31
Astellas and NeurogesX Sign Distribution and Marketing Agreement 31
Akela Pharma Inks Agreement with Teikoku Seiyaku 31
Medical Nutrition Inks Exclusive Licensing Agreement with DSE
Healthcare 32
Echo Therapeutics Inks a Licensing Deal with Ferndale Pharma 32
Circ Pharma Signs a Development Agreement with Elan 33
Orexo Inks Distribution Agreement with Neopharm 33
Orexo Inks Agreement with NovaMed Pharmaceuticals 33
Pharmos and Reperio Enter into Agreement 33
Caraco Pharmaceutical Launches Oxycodone Hydrochloride Tablet 34
Purdue Pharma Provides Labopharm’s RYZOLT 34
Bayer Acquires Sagmel’s OTC Business 34
E5 Pharma Receives Approval from FDA 34
Pharmaceutical Associates Receives Approval from FDA 34
Concord Receives New Drug Approvals 35
Hisamitsu Receives Approval for SALONPAs® 35
Johnson and Johnson Submits NDA to FDA 35
Nycomed and Paladin Inks Joint-Promotion Agreement for Tridural 35
Akela Extends Agreement with Janssen 35
Daiichi and Lead Chemical Receives Approval for LoxoninÃ’ Tape 35
Tokio Marine Capital Acquires Showa Yakuhin Kako 36
Corgenix Collaborates with Randox Laboratories 36
Corgenix Receives EPO Approval for Aspirin Resistance Method 36
IOL to Expand Production Capacity 36
American Oriental Bioengineering Partners with China Aoxing 36
Abraxis Takes Over Shimoda and its Subsidiary Company 36
Church and Dwight Snaps Up Del Pharmaceuticals from Coty 37
Sosei Group Corp Re-Acquires Rights to Commercialize AD 923 37
ProStrakan Group Inks Agreement with Paladin Labs 37
Anika Therapeutics Inks Distribution Agreement with DePuy Mitek 38
Wyeth Acquires ThermaCare Brand from PandG 38
Albemarle Appoints Dr. Reddy’s as Distributor of Bulk
Ibuprofen API 38
Competitive Technologies and ELS Join Forces to Distribute
Pain Management Device 39
Altea Therapeutics Partners with Hospira 39
Paladin Inks Co-Promotion Deal with Nycomed 39
AstraZeneca to Divest OTC Portfolio 40

10. CORPORTAE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 41
Ranbaxy Receives Approval from FDA 41
Wockhardt Receives FDA Approval for DPN + APAP 41
Alpharma to Market Flector® Patch in the US 41
Auriga and Mikart Inks Agreement to Market Codein 41
Watson Receives FDA Approval for Oxycodone Hydrochloride and
Ibuprofen 41
Labopharm’s Tramadol Receives Approval in Canada 41
Lion Acquires BUFFERIN® Trademark Rights 42
Grunenthal’s Extends Licensing Agreement with Ortho-McNeil 42
China Aoxing Pockets LRT 42
Anesiva Inks Joint Venture Agreement Wanbang 42
Beijing Med-Pharm Inks Agreement with Lotus Healthcare 42
LAB International Inks Licensing Agreement with Janssen
Pharmaceutica 43
Three Sixty Pockets Rockford-Montgomery Labs 43
Antares Enters into License and Development Agreement for
Opioid Analgesic 43
Abraxis BioScience Acquires AstraZeneca’s Analgesic Brand
Portfolio 43
IntelliPharmaCeutics Inks Agreement with Larasan 43
Ranbaxy and Ethypharm Ink In-licensing Agreement 44
Elite Collaborates with TPN to Co-develop Analgesic Drug 44
Novartis Acquires Hexal Company and Major Stake in Eon Labs . 44
NovaDel Pharma Receives Patent for Buccal Sprays Technology 44
Auxilium Pharmaceuticals Enters into a Licensing Agreement
with PharmaForm 44
EC Sanctions Sale of Elan’s Prialt 45
EpiCept Corp. Merges with Maxim Pharmaceuticals, Inc 45
Reckitt Benckiser plc Acquires Boots Healthcare International 45

11. FOCUS ON SELECT KEY PLAYERS 46
Bayer Consumer Care (US) 46
Johnson and Johnson (US) 46
McNeil Consumer Healthcare (Canada) 46
Novartis International AG (Switzerland) 46
Pfizer Inc. (US) 47
Reckitt Benckiser Group Plc (UK) 47
Sanofi Aventis S.A. (France) 47

12. GLOBAL MARKET PERSPECTIVE 48
Table 2: World Recent Past, Current and Future Analysis for
Analgesics by Geographic Region/Country - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years2007 through 2015 (includes
corresponding Graph/Chart) 48

Table 3: World Historic Review for Analgesics by Geographic
Region/Country - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 49

Table 4: World 11-Year Perspective for Analgesics by
Geographic Region/Country - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for
Years2005,2010 and 2015(includes corresponding Graph/Chart) 50

Table 5: World Recent Past, Current and Future Analysis for
Internal Analgesics by Geographic Region/ Country - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 51

Table 6: World Historic Review for Internal Analgesics by
Geographic Region / Country - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 52

Table 7: World 11-Year Perspective for Internal Analgesics by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 2005, 2010 and
2015 (includes corresponding Graph/Chart) 53

Table 8: World Recent Past, Current and Future Analysis for
Internal Analgesics by Product Segment - Aspirin,
Acetaminophen, Ibuprofen, and Others Markets Independently
Analyzed with Annual Sales Figures in US$ Million for
Years2007 through 2015 (includes corresponding Graph/Chart) 54

Table 9: World Historic Review for Internal Analgesics by
Product Segment - Aspirin, Acetaminophen, Ibuprofen, and
Others Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 55

Table 10: World 11-Year Perspective for Internal Analgesics by
Product Segment - Percentage Breakdown of Dollar Sales for
Aspirin, Acetaminophen, Ibuprofen, and Others Markets for
Years 2005, 2010 and 2015 (includes corresponding Graph/Chart) 56

Table 11: World Recent Past, Current and Future Analysis for
Aspirin by Geographic Region/Country - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years2007 through 2015 (includes
corresponding Graph/Chart) 57

Table 12: World Historic Review for Aspirin by Geographic
Region/Country - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 58

Table 13: World 11-Year Perspective for Aspirin by Geographic
Region/Country - Percentage Breakdown of Dollar Sales for US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets for Years 2005,2010and 2015
(includes corresponding Graph/Chart) 59

Table 14: World Recent Past, Current and Future Analysis for
Acetaminophen by Geographic Region/ Country - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years2007 through 2015
(includes corresponding Graph/Chart) 60

Table 15: World Historic Review for Acetaminophen by
Geographic Region/Country - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 61

Table 16: World 11-Year Perspective for Acetaminophen by
Geographic Region/Country - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia- Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
2005,2010 and 2015 (includes corresponding Graph/Chart) 62

Table 17: World Recent Past, Current and Future Analysis for
Ibuprofen by Geographic Region/Country - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years2007 through 2015 (includes
corresponding Graph/Chart) 63

Table 18: World Historic Review for Ibuprofen by Geographic
Region/Country - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 64

Table 19: World 11-Year Perspective for Ibuprofen by
Geographic Region/Country - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia- Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
2005,2010 and 2015 (includes corresponding Graph/Chart) 65

Table 20: World Recent Past, Current and Future Analysis for
Other Internal Analgesics by Geographic Region/Country - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years2007 through 2015
(includes corresponding Graph/Chart) 66

Table 21: World Historic Review for Other Internal Analgesics
by Geographic Region/Country - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 67

Table 22: World 11-Year Perspective for Other Internal
Analgesics by Geographic Region/Country - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for
Years2005,2010 and 2015 (includes corresponding Graph/Chart) 68

Table 23: World Recent Past, Current and Future Analysis for
External Analgesics by Geographic Region/ Country - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 2015
(includes corresponding Graph/Chart) 69

Table 24: World Historic Review for External Analgesics by
Geographic Region / Country - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2001 through 2007 (includes
corresponding Graph/Chart) 70

Table 25: World 11-Year Perspective for External Analgesics by
Geographic Region /Country - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for
Years2005,2010 and 2015(includes corresponding Graph/Chart) 71

13. THE UNITED STATES 72
A.Market Analysis 72
Current and Future Analysis 72
Pain Statistics in the US 72
Industry Overview 72
Internal Analgesics 73
Cox-2 Drugs in for Some Trouble 73
Switch to OTC Drugs 73
Table 26: US Analgesics Market (2009): Percentage Share
Breakdown of Leading Manufacturers by Sales (includes
corresponding Graph/Chart) 73

Table 27: US Internal Liquid Analgesics Market (2009):
Percentage Share Breakdown of Leading Brands by Sales
(includes corresponding Graph/Chart) 74

Table 28: US Internal Tablet Analgesics Market (2009):
Percentage Share Breakdown of Leading Brands by Sales
(includes corresponding Graph/Chart) 74

Table 29: Internal Analgesics Market in the US by Retail
Channel (2008): Percentage Share by Value Sales for
Discount Stores, Food/Drug Combination Stores, Chain Drug
Stores, Supermarkets, and Independent Drug Stores
(includes corresponding Graph/Chart) 75
Promotional Strategies for the Internal Analgesics 75
Table 30: Market for Internal Liquid Analgesics in the
U.S. by Retail Channel (2008): Percentage Share by Value
Sales for Supermarkets, Drug Stores, and Discounters
(includes corresponding Graph/Chart) 75
Pediatric Analgesics: The New Kid on the Block 75
External Analgesics 76
Stretching Boundaries 76
Table 31: US External Analgesics Market (2007):
Percentage Share Breakdown of Leading Ten Brands by
Revenues (includes corresponding Graph/Chart) 76

Table 32: External Analgesics Market in the US by Retail
Channel (2008): Percentage Share by Value Sales for Chain
drug stores, Discount stores, Food/drug combination
stores, Independent drug stores, and Supermarkets
(includes corresponding Graph/Chart) 76
Rubs, Patches: Driving the External Analgesics Market 77
Patch Relief Gaining Momentum 77
B.Market Analytics 77
Table 33: US Recent Past, Current and Future Analysis for
Analgesics by Product Segment - Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 77

Table 34: US Historic Review for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 78

Table 35: US 11-Year Perspective for Analgesics by Product
Segment - Percentage Breakdown of Dollar Sales for Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets for2005,2010 and 2015(includes
corresponding Graph/Chart) 79

14. CANADA 80
Market Analysis 80
Table 36: Canadian Recent Past, Current and Future Analysis
for Analgesics by Product Segment - Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years2007 through 2015 (includes
corresponding Graph/Chart) 80

Table 37: Canadian Historic Review for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 81

Table 38: Canadian 11-Year Perspective for Analgesics by
Product Segment - Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for2005,2010 and
2015(includes corresponding Graph/Chart) 82

15. JAPAN 83
A.Market Analysis 83
Current and Future Analysis 83
Competitive Scenario in the Past 83
Table 39: OTC Analgesics Market in Japan (2005): Market
Share of Leading Players by Value - Lion, Arax, Taisho
Pharmaceutical, SS Pharmaceutical, Shionogi, and Others
(includes corresponding Graph/Chart) 83
B.Market Analytics 84
Table 40: Japanese Recent Past, Current and Future Analysis
for Analgesics by Product Segment - Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years2007 through 2015 (includes
corresponding Graph/Chart) 84

Table 41: Japanese Historic Review for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 85

Table 42: Japanese 11-Year Perspective for Analgesics by
Product Segment - Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for2005,2010 and 2015
(includes corresponding Graph/Chart) 86

16. EUROPE 87
A.Market Analysis 87
Current and Future Analysis 87
By Product Group/Segment 87
European Pain Management Market 87
Generics Restrain Revenue Growth 87
Popular Brands in 2004 88
Table 43: Popular Brands of Pain and Inflammation Medication
in Europe (2004): Percentage Share of Aspirin, Voltaren,
Ibuprofen, Nurofen, Vioxx, Celebre, Tylenol, Aulin, Anadin,
and Paracetamol (includes corresponding Graph/Chart) 88
B.Market Analytics 89
Table 44: European Recent Past, Current and Future Analysis
for Analgesics by Geographic Region/Country - France,
Germany, UK, Italy, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years2007 through 2015 (includes corresponding
Graph/Chart) 89

Table 45: European Historic Review for Analgesics by
Geographic Region/Country - France, Germany, UK, Italy,
Spain, Russia and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2001 through 2006 (includes corresponding Graph/Chart) 90

Table 46: European 11-Year Perspective for Analgesics by
Geographic Region/Country - Percentage Breakdown of Dollar
Sales for France, Germany, UK, Italy, Spain, Russia and Rest
of Europe Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 91

Table 47: European Recent Past, Current and Future Analysis
for Analgesics by Product Segment - Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 92

Table 48: European Historic Review for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2007 (includes corresponding
Graph/Chart) 93

Table 49: European 11-Year Perspective for Analgesics by
Product Segment - Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for Years 2005, 2010 and
2015 (includes corresponding Graph/Chart) 94

16a. FRANCE 95
A.Market Analysis 95
Current and Future Analysis 95
Competitive Scenario 95
Table 50: Analgesics Market in France (2005): Market Share
of Leading Players by Value - Bristol-Myers Squibb,
Therapix, Roche, Bayer Group, Wyeth Consumer Healthcare,
and Others) (includes corresponding Graph/Chart) 95
B.Market Analytics 96
Table 51: French Recent Past, Current and Future Analysis for
Analgesics by Product Segment - Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years2007 through 2015 (includes
corresponding Graph/Chart) 96

Table 52: French Historic Review for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 97

Table 53: French 11-Year Perspective for Analgesics by
Product Segment - Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for2005,2010 and
2015(includes corresponding Graph/Chart) 98

16b. GERMANY 99
A.Market Analysis 99
Current and Future Analysis 99
Competitive Scenario 99
Table 54: Analgesics Market in Germany (2005): Market Share
of Leading Players by Value - Bayer Group, Boehringer
Ingelheim, Wyeth Consumer Healthcare, and Others (includes
corresponding Graph/Chart) 99
B.Market Analytics 100
Table 55: German Recent Past, Current and Future Analysis for
Analgesics by Product Segment - Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years2007 through 2015 (includes
corresponding Graph/Chart) 100

Table 56: German Historic Review for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 101

Table 57: German 11-Year Perspective for Analgesics by
Product Segment - Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for2005,2010 and
2015(includes corresponding Graph/Chart) 102

16c. ITALY 103
A.Market Analysis 103
Current and Future Analysis 103
Competitive Scenario 103
Table 58: Analgesics Market in Italy (2005): Market Share
of Leading Players by Value - Bayer Group, Angelini,
Novartis, Bristol-Myers Squibb, and Others (includes
corresponding Graph/Chart) 103
B.Market Analytics 104
Table 59: Italian Recent Past, Current and Future Analysis for
Analgesics by Product Segment - Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years2007 through 2015 (includes
corresponding Graph/Chart) 104

Table 60: Italian Historic Review for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 105

Table 61: Italian 11-Year Perspective for Analgesics by
Product Segment - Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for2005,2010 and 2015
(includes corresponding Graph/Chart) 106

16d. THE UNITED KINGDOM 107
A.Market Analysis 107
Current and Future Analysis 107
An Overview of Analgesics Market in the UK 107
Distribution Scenario 107
Competitive Scenario 108
Table 62: Analgesics Market in the United Kingdom (2005E):
Market Shares of Leading Players by Value - Boots
Healthcare, GlaxoSmithKline, and Others (includes
corresponding Graph/Chart) 108
B.Market Analytics 108
Table 63: UK Recent Past, Current and Future Analysis for
Analgesics by Product Segment - Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 108

Table 64: UK Historic Review for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) 109

Table 65: UK 11-Year Perspective for Analgesics by Product
Segment - Percentage Breakdown of Dollar Sales for Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets for 2005,2010 and
2015(includes corresponding Graph/Chart) 110

16e. SPAIN 111
A.Market Analysis 111
Current and Future Analysis 111
Competitive Scenario 111
Table 66: Analgesics Market in Spain (2005): Market Share
of Leading Players by Value - Bayer Group, Boehringer
Ingelheim, Bristol-Myers Squibb, Novartis, Boots
Healthcare, and Others (includes corresponding Graph/Chart) 111
B.Market Analytics 112
Table 67: Spanish Recent Past, Current and Future Analysis for
Analgesics by Product Segment - Internal Analgesics
(Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 112

Table 68: Spanish Historic Review for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006(includes corresponding
Graph/Chart) 113

Table 69: Spanish 11-Year Perspective for Analgesics by
Product Segment - Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for2005,2010 and 2015
(includes corresponding Graph/Chart) 114

16f. REST OF EUROPE 115
Market Analysis 115
Table 70: Rest of Europe Recent Past, Current and Future
Analysis for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years2007 through
2015 (includes corresponding Graph/Chart) 115

Table 71: Rest of Europe Historic Review for Analgesics by
Product Segment - Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 116

Table 72: Rest of Europe 11-Year Perspective for Analgesics
by Product Segment - Percentage Breakdown of Dollar Sales
for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen
and Others) and External Analgesics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 117

17. ASIA-PACIFIC 118
A.Market Analysis 118
Current and Future Analysis 118
The OTC Analgesic Market 118
OTC Analgesics Market in Asia-Pacific (2004): A Comparative
Analysis of the Major Regions - Australia, China and South
Korea 118
B.Market Analytics 119
Table 73: Asia-Pacific Recent Past, Current and Future
Analysis for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years2007 through
2015 (includes corresponding Graph/Chart) 119

Table 74: Asia-Pacific Historic Review for Analgesics by
Product Segment - Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 120

Table 75: Asia-Pacific 11-Year Perspective for Analgesics by
Product Segment - Percentage Breakdown of Dollar Sales for
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets for 2005,2010 and
2015(includes corresponding Graph/Chart) 121

18. LATIN AMERICA 122
Market Analysis 122
Table 76: Latin American Recent Past, Current and Future
Analysis for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 122

Table 77: Latin American Historic Review for Analgesics by
Product Segment - Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 123

Table 78: Latin American 11-Year Perspective for Analgesics
by Product Segment - Percentage Breakdown of Dollar Sales
for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen
and Others) and External Analgesics Markets for 2005, 2010 and
2015(includes corresponding Graph/Chart) 124

19. REST OF WORLD 125
Market Analysis 125
Table 79: Rest of World Recent Past, Current and Future
Analysis for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
and External Analgesics Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 125

Table 80: Rest of World Historic Review for Analgesics by
Product Segment - Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) 126

Table 81: Rest of World 11-Year Perspective for Analgesics
by Product Segment - Percentage Breakdown of Dollar Sales
for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen
and Others) and External Analgesics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 127

20. APPENDIX - POPULAR ANALGESIC BRANDS BY REGION 128
Canada 128
France 128
Germany 129
United Kingdom 130
Leading Analgesics Brands for Children 131
Italy 131
Spain 131
Rest of Europe 132
Asia-Pacific 139
Latin America 143


COMPETITION

Total Companies Profiled: 137 (including Divisions/Subsidiaries - 179)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 47
Canada 5
Japan 8
Europe 62
France 4
Germany 9
The United Kingdom 13
Italy 8
Spain 2
Rest of Europe 26
Asia-Pacific (Excluding Japan) 49
Middle East 6
Africa 2
------------------------------------------

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...

Detailed I/E report of Carbendazim export analysis

Detailed I/E report of Carbendazim export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Carbendazim export analysis will help clients indentify export situation of technical and formulations with exclusive research methods, to offer not only the target products' export volume, price, time, ...

Global Foot Care Products Industry

Global Foot Care Products Industry

  • $ 4 950
  • Industry report
  • July 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Foot Care Products in US$ by the following Product Segments: Devices, and Medication. The report provides separate comprehensive analytics for the US, Canada, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.